These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33512849)

  • 21. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
    Inciarte A; Leal L; González E; León A; Lucero C; Mallolas J; Torres B; Laguno M; Rojas J; Martínez-Rebollar M; González-Cordón A; Cruceta A; Arnaiz JA; Gatell JM; García F;
    J Antimicrob Chemother; 2017 Oct; 72(10):2857-2861. PubMed ID: 29091217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
    Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV Preexposure Prophylaxis: A Review.
    Riddell J; Amico KR; Mayer KH
    JAMA; 2018 Mar; 319(12):1261-1268. PubMed ID: 29584848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention.
    Van Epps P; Wilson BM; Garner W; Beste LA; Maier MM; Ohl ME
    J Acquir Immune Defic Syndr; 2019 Dec; 82(5):427-430. PubMed ID: 31714421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP.
    Younger J; Raboud J; Szadkowski L; Harrigan R; Walmsley S; Bayoumi AM; Klein MB; Cooper C; Burchell AN; Loutfy M; Hull M; Wong A; Thomas R; Hogg R; Montaner J; Tsoukas C; Antoniou T;
    Antivir Ther; 2019; 24(3):211-220. PubMed ID: 30873953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linking emergency department patients at risk for human immunodeficiency virus to pre-exposure prophylaxis.
    Mahal J; Deccy S; Seu R
    Am J Emerg Med; 2022 Apr; 54():87-90. PubMed ID: 35151016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The HIV Pre-exposure Prophylaxis (PrEP) Cascade at NYC Sexual Health Clinics: Navigation Is the Key to Uptake.
    Pathela P; Jamison K; Blank S; Daskalakis D; Hedberg T; Borges C
    J Acquir Immune Defic Syndr; 2020 Apr; 83(4):357-364. PubMed ID: 31904700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database.
    Rossotti R; Borghi V; Callegaro AP; Micheli V; Bruzzone B; Colao G; Gismondo MR; Vicenti I; Penco G; Zazzi M; Rusconi S
    J Clin Virol; 2016 Oct; 83():48-53. PubMed ID: 27591555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Scoping Review of the Current Landscape of Pre-Exposure Prophylaxis and Postexposure Prophylaxis in India.
    Goswami S; Borate S; Marupuru S; Marupuru S
    AIDS Patient Care STDS; 2024 Jul; 38(7):287-304. PubMed ID: 38800957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
    Melody K; Roy CN; Kline C; Cottrell ML; Evans D; Shutt K; Pennings PS; Keele BF; Bility M; Kashuba ADM; Ambrose Z
    J Virol; 2020 Mar; 94(8):. PubMed ID: 31969438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.
    TenoRes Study Group
    Lancet Infect Dis; 2016 May; 16(5):565-575. PubMed ID: 26831472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco.
    Shen M; Xiao Y; Rong L; Meyers LA; Bellan SE
    BMC Med; 2018 Apr; 16(1):58. PubMed ID: 29688862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Trends in Rates of Sexually Transmitted Infections Before vs After Initiation of HIV Preexposure Prophylaxis Among Men Who Have Sex With Men.
    McManus H; Grulich AE; Amin J; Selvey C; Vickers T; Bavinton B; Zablotska I; Vaccher S; Jin F; Holden J; Price K; Yeung B; Cabrera Quichua G; Ogilvie E; McNulty A; Smith D; Guy R
    JAMA Netw Open; 2020 Dec; 3(12):e2030806. PubMed ID: 33355675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
    Weis JF; Baeten JM; McCoy CO; Warth C; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Mugo N; Matsen FA; Celum C; Lehman DA;
    AIDS; 2016 Jan; 30(1):31-5. PubMed ID: 26731753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV Seroconversion in the Era of Pharmacologic Prevention: A Case-Control Study at a San Francisco STD Clinic.
    Johnson KA; Hessol NA; Kohn R; Nguyen TQ; Mara ES; Hsu L; Scheer S; Cohen SE
    J Acquir Immune Defic Syndr; 2019 Oct; 82(2):159-165. PubMed ID: 31192823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-exposure and postexposure prophylaxis access in rural versus urban pharmacies in Georgia and Pennsylvania.
    Kislovskiy Y; Pino N; Crawford ND; Woitas T; Cason S; Konka A; Kimble T; Olson I; Villarreal D; Jarlenski M
    J Am Pharm Assoc (2003); 2024; 64(4):102084. PubMed ID: 38574992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low clinical impact of HIV drug resistance mutations in oral pre-exposure prophylaxis: a systematic review and meta-analysis.
    Rachman BE; Khairunisa SQ; Wungu CDK; Asmarawati TP; Rusli M; Bramantono ; Arfijanto MV; Hadi U; Kameoka M; Nasronudin
    AIDS Res Ther; 2024 Jun; 21(1):37. PubMed ID: 38844950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.